Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Alabama
Clinical trial register · United States · industry-sponsored

Clinical Trials in Alabama, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9132 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 11 Oct 2026, 03:16 UTC
9132
Studies in scope
industry-sponsored, all four open statuses
4964
Recruiting now
open to new participants
2194
Lead sponsors
across recruiting studies
Top states
California 113 Florida 110 Massachusetts 66 Georgia 63 Illinois 63
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca68 Eli Lilly and Company49 Novartis Pharmaceuticals48 AbbVie44 Hoffmann-La Roche38 Clear sponsor filter
State
California113 Florida110 Massachusetts66 Georgia63 Illinois63
All 47 states
Target enrolment
to

Trials with a site in Alabama

48 of 9132 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Recruiting
Novartis Pharmaceuticals
Phase 2
259
Alabama, California, Florida, Georgia, Indiana, Kansas, Louisiana, Michigan
2026-09-10
Recruiting
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
NCT07768371IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
576
Alabama, Arizona, Arkansas, California, Georgia, Illinois, Maryland, Michigan
2026-08-27
Recruiting
Novartis Pharmaceuticals
Phase 2
120
Alabama, California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2026-05-29
Recruiting
Novartis Pharmaceuticals
Phase 3
5,700
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2026-05-11
Recruiting
Novartis Pharmaceuticals
Phase 3
770
Alabama, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2026-03-24
Recruiting
Novartis Pharmaceuticals
Phase 2
210
Alabama, California, Florida, Indiana, Michigan, Nebraska, Nevada, New York
2026-03-09
Recruiting
Novartis Pharmaceuticals
Phase 1/2
181
Alabama, Iowa, Kansas, North Carolina, South Carolina, Utah
2026-01-13
Recruiting
Novartis Pharmaceuticals
Observational
1,000
Alabama, California, Connecticut, Florida, Illinois, Maryland, Missouri, New York
2025-12-17
Active, closed
Novartis Pharmaceuticals
Phase 2
234
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-12-02
Recruiting
Novartis Pharmaceuticals
Phase 3
1,275
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Hawaii
2025-11-11
Recruiting
Novartis Pharmaceuticals
Phase 3
400
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida
2025-07-11
Recruiting
Novartis Pharmaceuticals
Phase 3
940
Alabama, California, Colorado, Florida, Georgia, Illinois, Iowa, Kansas
2025-07-01
Recruiting
Pelacarsen Roll-over Extension Program
NCT06875973Atherosclerotic Cardiovascular Disease
DrugPelacarsen
Novartis Pharmaceuticals
Phase 3
599
Alabama, Arkansas, California, Florida, Georgia, Illinois, Louisiana, Maryland
2025-05-19
Recruiting
Novartis Pharmaceuticals
Phase 2
224
Alabama, Arkansas, California, District of Columbia, Florida, Georgia, Kentucky, Massachusetts
2025-05-16
Active, closed
Novartis Pharmaceuticals
Phase 3
246
Alabama, Arizona, California, Florida, Illinois, Indiana, Louisiana, Maryland
2025-04-30
Active, closed
Novartis Pharmaceuticals
Phase 2
396
Alabama, Arizona, California, Florida, Georgia, Idaho, Illinois, Indiana
2025-03-26
Active, closed
Novartis Pharmaceuticals
Phase 3
565
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts
2025-03-20
Active, closed
Novartis Pharmaceuticals
Phase 3
196
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2025-03-13
Recruiting
Novartis Pharmaceuticals
Phase 2
20
Alabama, California, Florida, Georgia, Idaho, Nevada, Ohio, Texas
2025-02-21
Active, closed
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
NCT06665256Idiopathic Inflammatory Myopathies
DrugRapcabtagene autoleucel
Novartis Pharmaceuticals
Phase 2
21
Alabama, Florida, Georgia, Illinois, Iowa, North Carolina, Pennsylvania, Texas
2024-12-17
Recruiting
Novartis Pharmaceuticals
Phase 3
354
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Kentucky, Maryland
2024-10-24
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Alabama, California, Florida, Massachusetts, Michigan, Minnesota, Texas, Washington
2024-10-15
Active, closed
Novartis Pharmaceuticals
Phase 2
179
Alabama, California, Illinois, Iowa, Kentucky, Massachusetts, Missouri, North Carolina
2024-09-04
Recruiting
Novartis Pharmaceuticals
Phase 1/2
161
Alabama, Florida, Massachusetts, New York, North Carolina, Pennsylvania, Rhode Island, Texas
2024-08-15
Active, closed
Novartis Pharmaceuticals
Phase 2
155
Alabama, California, Florida, Georgia, Indiana, Louisiana, Michigan, Ohio
2024-07-02
Recruiting
Novartis Pharmaceuticals
Phase 3
550
Alabama, California, Colorado, Florida, Georgia, Illinois, Louisiana, Maryland
2024-05-21
Recruiting
Novartis Pharmaceuticals
Phase 2
502
Alabama, California, Florida, Kansas, Massachusetts, Michigan, Minnesota, New Jersey
2024-03-07
Recruiting
Novartis Pharmaceuticals
Phase 3
1,400
Alabama, Alaska, Arizona, Arkansas, California, Colorado, District of Columbia, Florida
2024-02-28
Active, closed
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
A Study of Zigakibart in Adults With IgA Nephropathy
NCT05852938IgA Nephropathy, Immunoglobulin A Nephropathy
DrugZigakibart
Novartis Pharmaceuticals
Phase 3
383
Alabama, California, Colorado, Florida, Illinois, Indiana, Iowa, Minnesota
2023-07-06
Active, closed
Novartis Pharmaceuticals
Phase 3
288
Alabama, California, Florida, Georgia, Illinois, Kentucky, Louisiana, Maryland
2023-04-21
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-03-09
Active, closed
Novartis Pharmaceuticals
Phase 3
436
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2023-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
696
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2022-12-09
Active, closed
Novartis Pharmaceuticals
Phase 2
34
Alabama, Alaska, Arizona, California, Colorado, Connecticut, Florida, Georgia
2022-11-11
Active, closed
Novartis Pharmaceuticals
Phase 3
452
Alabama, California, Florida, Georgia, Louisiana, Michigan, Nevada, New York
2022-07-14
Active, closed
Novartis Pharmaceuticals
Phase 3
610
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Illinois, Indiana
2022-07-08
Active, closed
Novartis Pharmaceuticals
Phase 4
136
Alabama, Arizona, California, Florida, Idaho, Louisiana, Maryland, Massachusetts
2022-03-02
Active, closed
Novartis Pharmaceuticals
Phase 3
17,004
Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia
2021-11-23
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Alabama, California, Florida, Illinois, Iowa, Michigan, Minnesota, Missouri
2021-07-30
Recruiting
Novartis Pharmaceuticals
Phase 4
130
Alabama, District of Columbia, Georgia, North Carolina, Pennsylvania, Texas
2021-06-10
Active, closed
Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)
NCT04603495Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharmaceuticals
Phase 3
430
Alabama, Arizona, California, Connecticut, Florida, Illinois, Indiana, Kentucky
2021-04-09
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
DrugsAtrasentan·Zigakibart
Novartis Pharmaceuticals
Phase 3
404
Alabama, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2020-12-11
Active, closed
Novartis Pharmaceuticals
Phase 2
121
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Indiana
2019-06-24
Active, closed
Novartis Pharmaceuticals
Phase 3
1,882
Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Hawaii
2018-12-28
Active, closed
Novartis Pharmaceuticals
Phase 3
5,101
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2018-12-07
Active, closed
Ribociclib (LEE011) Rollover Study for Continued Access
NCT02934568Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
DrugRibociclib
Novartis Pharmaceuticals
Phase 2
22
Alabama, Massachusetts, Michigan, New York, Tennessee
2016-12-15
Active, closed
Novartis Pharmaceuticals
Phase 3
240
Alabama, California, Florida, Massachusetts, Michigan, New Jersey, Pennsylvania, Utah
2013-07-26
Rows per page Showing 1–48 of 48
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-usa/state/alabama

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,132 studies in total at the last sync on 11 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 48 of those studies with a site in Alabama that also match the filters currently applied.

How many clinical trials are recruiting in Alabama?

22 of the 48 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:16 UTC sync. A further 0 have not yet opened recruitment, 26 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Alabama), 48 studies
PhaseStudiesRecruitingShare
Phase 3271056.3%
Phase 214629.2%
Phase 1/2336.3%
Phase 4214.2%
Observational112.1%
Phase 1112.1%

Most active sponsors

Lead sponsors with the most studies (Alabama)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals4822
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.